A Phase IIb Study to Investigate PD-0325901 as Monotherapy for Neurofibromatosis Type 1 Patients with Plexiform Neurofibromas
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2018
At a glance
- Drugs PD 325901 (Primary)
- Indications Neurofibromatoses; Plexiform neurofibroma
- Focus Therapeutic Use
- Sponsors SpringWorks Therapeutics
- 05 Nov 2018 According to a SpringWorks Therapeutics media release, this trial will be initiated in the first half of 2019.
- 18 Sep 2018 New trial record
- 05 Sep 2018 According to a BeiGene media release, SpringWorks Therapeutics plans to initiate this trial in 2019.